Dovepress 15. Schrag A, Munchau A, Bhatia KP, Quinn NP, Marsden CD. Essen- tial tremor: an overdiagnosed condition? J Neurol. 2000;247: 955–959. 16. Deuschl G, Bain P, Brin M, Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord. 1998;(13 Suppl 3):2–23. 17. Deuschl G, Elble R. Essential tremor – neurodegenerative or non- degenerative disease towards a working definition of ET. Mov Disord. 2009;24:2033–2041. 18. Louis ED, Ottman R, Ford B, Pullman S, Martinez M, Fahn S, Hauser WA. The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research. Neuroepidemiology. 1997;16:124–133. 19. Fahn SE, Tolosa E, Marin C. Clinical rating scale for tremor. In: Jankovic J, Tolosa E, editors. Parkinson’s Disease and Movement Disorders, 2nd ed. Baltimore, MA: Williams and Wilkins; 1988:225–234. 20. Elble RJ, Pullman SL, Matsumoto JY, Raethjen J, Deuschl G, Tintner R; Tremor Research Group. Tremor amplitude is logarithmi- cally related to 4- and 5-point tremor rating scales. Brain. 2006;129 (Pt 10):2660–2666. 21. Gironell A, Kulisevsky J, Pascual-Sedano B, Flamarich D. Effect of amantadine in essential tremor: a randomized, placebo-controlled trial. Mov Disord. 2006;21:441–445. 22. Deng H, Le W, Jankovic J: Genetics of essential tremor. Brain. 2007, 130:1456–1464. 23. Gulcher JR, Jonsson P, Kong A, Kristjansson K, Frigge ML, Karason A, et al. Mapping of a familial essential tremor gene, FET1, to chromosome 3q13. Nat Genet. 1997;17:84–87. 24. Higgins JJ, Pho LT, Nee LE. A gene (ETM) for essential tremor maps to chromosome 2p22-p25. Mov Disord 1997;12:859–864. 25. Shatunov A, Sambuughin N, Jankovic J, Elble R, Lee HS, Singleton AB, et al. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain. 2006;129:2318–2331. 26. Louis ED, Ford B, Frucht S, Barnes LF, Tang MX, Ottman R. Risk of tremor and impairment from tremor in relatives of patients with essential tremor: a community-based family study. Ann Neurol. 2001;49:761–769. 27. Louis ED. Etiology of essential tremor: should we be searching for environmental causes? Mov Disord. 2001;16:822–829. 28. E l bl e R J. A n i m a l m o d e l s o f a c t i o n t r e m o r. M ov D i s o rd . 1998;13 Suppl 3:35–39. 29. Louis ED, Faust PL, Vonsattel JP, et al. Torpedoes in Parkinson’s disease, Alzheimer’s disease, essential tremor, and control brains. Mov Disord. 2009;24:1600–1605. 30. Louis ED, Faust PL, Vonsattel JP, et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain. 2007;130(Pt 12):3297–3307. 31. Shaikh AG, Kiura K, Optican LM, Ramat S, Tripp RM, Zee DS. Hypothetical membrane mechanisms in essential tremor. J Transl Med. 2008;6(1):68. 32. Benito-León J, Louis ED, Bermejo-Pareja F; Neurological Disorders in Central Spain Study Group. Risk of incident Parkinson’s disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry. 2009;80:423–425. 33. Minen MT, Louis ED. Emergence of Parkinson’s disease in essential tremor: a study of the clinical correlates in 53 patients. Mov Disord. 2008;23:1602–1605. 34. Zesiewcz TA, Elble R, Louis ED, et al. Practice parameter: Therapies for essential tremor. Report of the Quality Standards Subcommit- tee of the American Academy of Neurology. Neurology. 2005;64: 2008–2020. 35. Cleeves L, Findley LJ. Propranolol and propranolol-LA in essen- tial tremor: a double blind comparative study. J Neurol Neurosurg Psychiatry. 1988;51:379–384. 36. Koller WC. Long-acting propranolol in essential tremor. Neurology. 1985;35:108–110. Neuropsychiatric Disease and Treatment 2010:6 Overview of essential tremor 37. Jefferson D, Jenner P, Marsden CD. Beta-Adrenoreceptor antagonists in essential tremor. J Neurol Neurosurg Psychiatry. 1979;42:904–909. 38. Leigh PN, Jefferson D, Twomey A, et al. Beta-adrenoreceptor mecha- nisms in essential tremor; a double-blind placebo controlled trial of metoprolol, sotalol and atenolol. J Neurol Neurosurg Psychiatry. 1983;46:710–715. 39. Koller WC. Nadolol in essential tremor. Neurology. 1983;33:1076–1077. 40. Biary N, Bahou Y, Sofi MA, et al. The effect of nimodipine on essential tremor. Neurology. 1995;45:1523–1525. 41. Topaktas S, Onur R, Dalkara T. Calcium channel blockers and essential tremor. Eur Neurol. 1987;27:114–119. 42. O’Suilleabhain P, Dewey RB. Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord. 2002;17:383–386. 43. Gironell A, Kulisevsky J, Barbonoj M, et al. A randomized placebo- controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol. 1999;56:475–480. 44. Ondo W, Hunter C, Vuong KD, et al. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15:678–682. 45. Pahwa R, Lyons K, Hubble JP, et al. Double-blind, controlled trial of gabapentin in essential tremor. Mov Disord. 1998;13:465–467. 46. Galvez-Jimenez N, Hargreave M. Topiramate and essential tremor. Ann Neurol. 2000;47:837–838. 47. Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology. 2002;59:132–134. 48. Ondo WG, Jankovic J, Connor GS, et al; Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006;66:672–677. 49. Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol. 2008;31:97–103. 50. Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord. 2005;11:101–103. 51. Bushara KO, Malik T, Exconde RE. The effect of levetiracetam on essential tremor. Neurology. 2005;64:1078–1080. 52. Sullivan KL, Hauser RA, Zesiewicz TA. Levetiracetam for the treatment of essential tremor. Mov Disord. 2005;20:640. 53. Zesiewicz TA, Ward CL, Hauser RA, et al. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord. 2007;22:1660–1663. 54. Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. Efficacy and tolerability of pregabalin in essential tremor: a random- ized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009;285(1–2):195–197. 55. Hallett M, Ravits J, Dubinsky RM, et al. A double-blind trial of isoniazid for essential tremor and other action tremors. Mov Disord. 1991;6:253–256. 56. Pahwa R, Lyons KE. Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study. Mov Disord. 2004;18:584–587. 57. Koller WC. Tradozone in essential tremor. Clin Neuropharmacol. 1989;12:134–137. 58. Cleeves J, Findley LJ. Trazodone is ineffective in essential tremor. J Neurol Neurosurg Psychiatry. 1990;53:268–269. 59. Ceravolo R, Salvetti S, Piccini P, et al. Acute and chronic effects of clozapine in essential tremor. Mov Disord. 1999;14:468–472. 60. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand. 1986;73:295–297. 61. Baruzzi A, Procaccianti G, Martinelli P, et al. Phenobarbital and pro- pranolol in essential tremor: a double-blind controlled clinical trial. Neurology. 1983;33:296–300. 62. Sasso E, Perucca E, Calzetti S. Double-blind comparison of primidone and phenobarbital in essential tremor. Neurology. 1988;38:808–810. 63. Gunal DI, Afsar N, Bekiroglu N, et al. New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. Neurol Sci. 2000;21:315–317. submit your manuscript | www.dovepress.com Dovepress 407